Liang becomes new CEO, prez at Medrad
Bayer Medical Care has appointed Samuel M. Liang as incoming president and CEO of Medrad, a cardiovascular device company, upon the retirement of John Friel later this year. Liang will succeed Friel as of July 1.
Liang has been president and CEO of Vascular Therapies, a start-up company in Totowa, N.J., that develops a combination drug-device product for surgery, since July 2008, Medrad reported.
Previously, he spent 24 years at Cordis, a Johnson & Johnson company, in engineering, international and commercial roles including vice president of marketing for Cordis Cardiology, worldwide vice president of commercial operations for Cordis Endovascular and disease state leader/general manager of Cordis Neurovascular.
Liang also was vice president of the Cordis’ global stent franchise and worldwide vice president for Cypher programs, where he led the company’s stent franchise and its drug-eluting stent initiatives, including launching Cypher.
Liang has been president and CEO of Vascular Therapies, a start-up company in Totowa, N.J., that develops a combination drug-device product for surgery, since July 2008, Medrad reported.
Previously, he spent 24 years at Cordis, a Johnson & Johnson company, in engineering, international and commercial roles including vice president of marketing for Cordis Cardiology, worldwide vice president of commercial operations for Cordis Endovascular and disease state leader/general manager of Cordis Neurovascular.
Liang also was vice president of the Cordis’ global stent franchise and worldwide vice president for Cypher programs, where he led the company’s stent franchise and its drug-eluting stent initiatives, including launching Cypher.